GeoVax Raises $3 Million in Private Placement to Fund Vaccine Development

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced it has entered into a securities purchase agreement with existing institutional investors for a private placement financing expected to raise approximately $3 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules and is anticipated to close on or about May 19, 2026.

Under the terms, GeoVax will sell 2,027,027 shares of common stock (or common stock equivalents) along with Series A warrants to purchase up to 2,027,027 shares at $1.48 per share with a five-year term, and Series B warrants to purchase up to 2,027,027 shares at $1.48 per share with an 18-month term. The net proceeds will be used for working capital and general corporate purposes, providing the company with additional financial flexibility as it advances its key programs.

The financing comes at a critical time for GeoVax, which is preparing to initiate a pivotal Phase 3 clinical trial for its lead vaccine candidate, GEO-MVA, targeting mpox and smallpox. This program is advancing under an expedited regulatory pathway and addresses urgent global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. The company also continues development of Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity in solid tumors, and GEO-CM04S1, a next-generation COVID-19 vaccine candidate for immunocompromised patients.

“This investment from existing institutional investors underscores confidence in our development strategy and the potential of our pipeline,” said a company spokesperson. “The funds will support our mission to address high-consequence infectious diseases and solid tumor cancers.”

A.G.P./Alliance Global Partners is serving as the sole placement agent. The offering is being conducted in reliance on exemptions from registration under the Securities Act of 1933, and GeoVax has agreed to file a registration statement with the SEC covering the resale of the shares and underlying common warrants.

This private placement provides GeoVax with a capital runway to advance its clinical programs toward key milestones, including the planned Phase 3 trial for GEO-MVA. The company’s ability to secure funding from existing investors signals continued support for its strategic focus on vaccines and immunotherapies with significant public health implications.

For more information about GeoVax and its pipeline, visit www.geovax.com.